个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Cheng, Y.[1] * ; Wu, L.[2] ; Huang, D. Z.[3] ; Wang, Q. M.[4] ; Fan, Y.[5] ; Liu, Z. F.[6] ; Fan, H. J.[7] ; Yao, W. X.[8] ; Liu, B. G.[9] ; Yu, G. H.[10] ; Pan, Y. Y.[11] ; Xu, F.[12] ; He, Z. Y.[13] ; Dong, X. R.[14] ; Ma, R.[15] ; Min, X. H.[16] ; Ge, X. S.[17] ; Chen, H. L.[18] ; Liu, Q.[19] ; Hu, Y. P.[20] ; Liu, Y.[1] ; Song, W. J.[21] ; Yang, C.[21] ; Sun, S. G.[21] ;
机构： [1]Jilin Canc Hosp, Changchun, Peoples R China [2]Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Affiliated Canc Hosp, Changsha, Peoples R China [3]Tianjin Med Univ, Canc Hosp & Inst, Tianjin, Peoples R China [4]Henan Canc Hosp, Zhengzhou, Peoples R China [5]Univ Chinese Acad Sci, Zhejiang Canc Hos, Canc Hosp, Hangzhou, Peoples R China [6]Shandong Canc Hosp & Inst, Shandong, Peoples R China [7]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [8]Sichuan Canc Hosp, Sichuan, Peoples R China [9]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [10]Weifang Peoples Hosp, Weifang, Peoples R China [11]USTC, Affiliated Hosp 1, Hefei, Peoples R China [12]Nanchang Univ, Affiliated Hosp 1, Nanchang, Peoples R China [13]Fujian Canc Hosp, Fujian, Peoples R China [14]Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Union, NJ USA [15]Liaoning Canc Hosp, Shenyang, Peoples R China [16]Anhui Chest Hosp, Hefei, Peoples R China [17]Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China [18]Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China [19]Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China [20]Hubei Canc Hosp, Wuhan, Peoples R China [21]Jiangsu Simcere Pharmaceut Co Ltd, Shanghai, Peoples R China
出处：
ISSN：

关键词： Trilaciclib SCLC Myelopreservation

语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2022]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Jilin Canc Hosp, Changchun, Peoples R China
推荐引用方式(GB/T 7714)：
Cheng Y.,Wu L.,Huang D. Z.,et al.Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)[J].JOURNAL OF THORACIC ONCOLOGY.2022,17(9):S437-S437.
APA：
Cheng, Y.,Wu, L.,Huang, D. Z.,Wang, Q. M.,Fan, Y....&Sun, S. G..(2022).Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES).JOURNAL OF THORACIC ONCOLOGY,17,(9)
MLA：
Cheng, Y.,et al."Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES)".JOURNAL OF THORACIC ONCOLOGY 17..9(2022):S437-S437

相关文献

[1]Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001) [2]VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis. [3]VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis. [4]PET imaging of CXCR4 expression using [18F]AlF-NOTA-QHY-04 for hematologic malignancy and solid tumors [5]Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250) [6]Durvalumab Plus Anlotinib Versus Durvalumab as Maintenance Treatment in ES-SCLC (DURABLE): A Randomized, Phase 2 Trial [7]Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. [8]Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES) [9]Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial [10]一项在复发性SCLC受试者中评价I-DXd的3期研究

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号